SITE009-0016

SITE009 (AUS) › SITE009-0016

SITE009-0016

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2025-09-17

enrolled

AEs

3

Serious

1

Dropout signal

–

Adverse events

3

Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2022-12-11 (study day 267); relationship: NOT RELATED

mild assessed

Grade 4 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 204); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-22 (study day 187); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.